IMUNON's PlaCCine® platform shows advantages over mRNA vaccines, demonstrating durability and safety in a Phase 1 COVID-19 trial. IMUNON, Inc. announced promising results from its Phase 1 ...

Company’s PlaCCine® technology platform demonstrates better durability and other advantages compared to mRNA vaccines Results further validate PlaCCine as a novel vaccine platform with potential ...

Q1 2025 Management View President & CEO Stacy Lindborg announced the initiation of the first clinical site in Imunon's ...

IMNN READ THE FULL IMNN RESEARCH REPORT Business Update First Site Activated for Phase 3 OVATION 3 Trial of IMNN-001 in ...

IMUNON initiates Phase 3 OVATION 3 study for IMNN-001 in advanced ovarian cancer; Phase 2 data accepted for ASCO presentation. IMUNON, Inc. has initiated the first trial site for its Phase 3 ...

Analysts estimate that Imunon will report an earnings per share (EPS) of $-0.36. Investors in Imunon are eagerly awaiting the ...

“IMUNON continues to make significant strides towards our goal of transforming the treatment landscape for women with advanced ovarian cancer. In 2024, our Phase 1/2 OVATION 2 Study delivered ...

Application error: a client-side exception has occurred (see the browser console for more information).

In the Phase 1 trial, designed to demonstrate the advantages of IMUNON’s technology compared to approved messenger RNA (mRNA) vaccines, IMNN-101 was administered as a single dose vaccine without ...